Release details

2014-04-11 10:43 CEST
  • Print
  • Share Share
no en

PCI Biotech: Successful completion of the first dose cohort in the study for patients with inoperable bile duct cancer

Lysaker, 11 April 2014 - PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today that the treatment evaluation of the first dose cohort in the phase I/II study of Amphinex in combination with the cytotoxic agent gemcitabine in patients with inoperable bile duct cancer (cholangiocarcinoma) is completed. No safety concerns were observed at this dose level.

A Cohort Review Committee (CRC) of clinical experts and company representatives has been established to evaluate the results and provide recommendation for the continuation of the study. The CRC has recommended that the study progresses into the next dose in accordance with the study protocol. Patients for the next dose cohort are currently being screened and will be treated with Amphinex® as soon as possible.

About PCI Biotech
PCI Biotech is a Norwegian biopharmaceutical company developing a novel light directed treatment system based on its patented photochemical internalization (PCI) technology. Originating from world leading research at the Norwegian Radium Hospital, the PCI method involves first injecting the photosensitizer Amphinex® and thereafter the therapeutic drug to be specifically delivered to the diseased cells. When the diseased cells are illuminated the cells' endosomes are ruptured to allow successful intracellular delivery of the drug.

PCI can enhance the delivery of all molecules taken into the cell by endocytosis. This includes most types of macromolecules, drugs carried by antibodies or nanoparticles, as well as some small molecule drugs.

The PCI technology is also a versatile and innovative vaccination platform, which may specifically increase the cytotoxic T-cell response of vaccines. This is particularly important in therapeutic vaccination, when the immune system needs to recognise and destroy diseased cells (e.g. virus infected cells and cancer).

PCI Biotech follows a strategy to create value by improving the effect both of existing cancer drugs and by realizing the large potential in new therapeutics, including therapeutic vaccines.

For more information visit: www.pcibiotech.com

Contact information:
PCI Biotech Holding ASA, Strandveien 55, N-1366 Lysaker
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 91 79 34 29
Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 94 00 57 57 

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
HUG#1776700